(Q36245510)

13 August 2017

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Christina H Yeon

1

1 reference

PubMed ID

16133791

13 August 2017

Mark D Pegram

series ordinal

2

1 reference

13 August 2017

1 October 2005

1 reference

Investigational New Drugs

13 August 2017

1 reference

13 August 2017

23

1 reference

13 August 2017

391-409

1 reference

13 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-005-2899-8

13 August 2017

0 references

cites work

HER2 as a prognostic factor in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2899-8

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2899-8

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2899-8

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2899-8

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2899-8

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

12 December 2020

Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors

1 reference

12 December 2020

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

12 December 2020

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

1 reference

12 December 2020

Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth

1 reference

12 December 2020

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

12 December 2020

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

12 December 2020

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

12 December 2020

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group

1 reference

12 December 2020

Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

1 reference

12 December 2020

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium

1 reference

12 December 2020

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

12 December 2020

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

1 reference

12 December 2020

Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients

1 reference

12 December 2020

Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

1 reference

12 December 2020

Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.

1 reference

12 December 2020

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

12 December 2020

Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy

1 reference

12 December 2020

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases

1 reference

12 December 2020

Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation

1 reference

12 December 2020

Interleukin-12 in anti-tumor immunity and immunotherapy.

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

12 December 2020

Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer

1 reference

12 December 2020

Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

12 December 2020

Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor

1 reference

12 December 2020

Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer

1 reference

12 December 2020

Trastuzumab-associated cardiotoxicity

1 reference

12 December 2020

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

12 December 2020

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

12 December 2020

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue

1 reference

12 December 2020

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

12 December 2020

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

12 December 2020

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

1 reference

12 December 2020

Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

1 reference

12 December 2020

The development and clinical use of trastuzumab (Herceptin).

1 reference

12 December 2020

Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients.

1 reference

12 December 2020

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

12 December 2020

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

12 December 2020

Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion

1 reference

12 December 2020

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

12 December 2020

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

12 December 2020

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

1 reference

12 December 2020

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Basic science of HER-2/neu: a review

1 reference

12 December 2020

Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer

1 reference

12 December 2020

Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

1 reference

12 December 2020

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

12 December 2020

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells

1 reference

12 December 2020

Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

1 reference

12 December 2020

Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression

1 reference

12 December 2020

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

1 reference

12 December 2020

Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers

1 reference

12 December 2020

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1 reference

12 December 2020

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

1 reference

12 December 2020

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

12 December 2020

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

12 December 2020

Biology of HER2 and its importance in breast cancer

1 reference

12 December 2020

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

12 December 2020

Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress

1 reference

12 December 2020

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

1 reference

12 December 2020

Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.

1 reference

12 December 2020

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

12 December 2020

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

12 December 2020

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

12 December 2020

1 reference

12 December 2020

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

12 December 2020

10.1007/S10637-005-2899-8

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16133791